News

Public Health Dean Donna Arnett is a panel participant for the ASPPH Virtual Annual Meeting, focused on lessons learned during the COVID-19 pandemic.

“Our results suggest that light measures don’t work, and strong measures do," said Charles Courtemanche.

For the RAPID project, the team will create a membrane mask and other flat sheet materials with a more porous and spongy structure that will include charged domain and enzymes, which would capture and effectively deactivate SARS-CoV-2, the virus that causes COVID-19.

A group of UK professors and scientists efforts to identify possible direct therapeutic approaches to treat COVID-19 was published in the Perspectives section of the most recent issue of Science, a journal of the American Association for the Advancement of Science (AAAS).

UK researchers have launched antibody testing that will help to understand what immunity to COVID-19 really means. The research is part of UK’s CURE Alliance team, which is uniting UK researchers across disciplines in the fight against the novel coronavirus.

“We are pleased to be able to offer this clinical trial to patients with COVID-19 in Kentucky. While there is no standard treatment for COVID-19, this trial gives us the ability to test multiple therapies rapidly in order to identify the most promising agents.”

The Kentucky Conference on Health Communication (KCHC), which was supposed to be held April 2-4, 2020, at the Hyatt Regency in Lexington, made the swift change to a virtual conference amid the COVID-19 pandemic.

According to the report, confirmed COVID-19 cases in the Commonwealth would have reached a staggering 45,000 by April 25 without any state-imposed measures. For comparison, the current total of confirmed COVID-19 cases is fewer than 4,000.

The UK CURE Alliance, in collaboration with the UK Center for Clinical and Translational Science, has issued RFAs for COVID-19 funding in three categories: health, materials and methods and social sciences. Full-time UK faculty in all title series are eligible to apply.

Sutton is the first UK researcher to receive funding for COVID-19 related work as part of the NSF's Rapid Response Research (RAPID) grant program, which enables the agency to quickly process and support research that addresses an urgent need.